New York, December 21, 2023 - Palatin Technologies, Inc. (NYSE American: PTN) has completed the sale of Vyleesi® to Cosette Pharmaceuticals, a US-based, specialty pharmaceutical company, for up to $171 million. Vyleesi is the first and only as-needed FDA-approved treatment for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). https://prismmarketview.com/companies/palatin-technologies-inc/ Carl Spana, Ph.D., President and Chief Executive Officer of...